device. Conclusions: In this large real-world study of inadequately-controlled asthma patients in primary care settings, the treatment with budesonide/formoterol FDC with the Elpenhaler ? device was associated with significant improvement in patients asthma control and quality of life....
INTRODUCTION Very limited real-world data have been captured in the Greek asthmatic population regarding the effects of treatment with a fixeddose combination of budesonide/formoterol via the Elpenhaler device, on the course of the disease and its impact on the patients' quality of life score. ...
Conclusions: The administration of FDC of fluticasone propionate and salmeterol, (500 + 50 mcg) via the Elpenhaler device for COPD, resulted in a well‐maintained or slight increase in treatment adherence and a subsequent benefit in health status, which further persisted after 3 months...
and MRC dyspnea score between COPD patients with at least one CV comorbidity versus those without comorbidities treated with fluticasone/salmeterol fixed dose combination (FDC) via Elpenhaler device for 12 months.Methods: Prospective, multicenter, non-interventional study (NCT02978703). Effectiveness ...
are the cornerstone of asthma treatment, therefore, patient adherence is very important.We performed a multicenter, open, non-interventional, observational, prospective study of 716 adult patients diagnosed with asthma receiving FDC (Fixed-dose combination) budesonide/formoterol via the Elpenhaler device...